Trinity Biotech (TRIB) Liabilities and Shareholders Equity (2009 - 2025)

Trinity Biotech's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $105.2 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 1.82% year-over-year to $105.2 million; the TTM figure through Dec 2025 stood at $405.5 million (up 5.22% YoY), while the FY2025 annual figure was $105.2 million, up 1.82% from the prior year.
• Liabilities and Shareholders Equity came in at $105.2 million for Q4 2025 at Trinity Biotech, up from $99.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $136.0 million in Q1 2021 to a low of $59.4 million in Q4 2023.
• A 5-year average of $99.0 million and a median of $98.8 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 35.47% in 2023 and jumped 73.79% in 2024, its largest moves.
• Trinity Biotech's Liabilities and Shareholders Equity stood at $118.9 million in 2021, then retreated by 22.53% to $92.1 million in 2022, then slumped by 35.47% to $59.4 million in 2023, then surged by 73.79% to $103.3 million in 2024, then grew by 1.82% to $105.2 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $105.2 million, $99.6 million, and $103.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison